631.25
-9.28%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Supriya Lifescience
Its shares trade on NSE under the ticker SUPRIYA.NS. It has been listed since 28 December 2021. In the fiscal year to 31 March 2026, it reported revenue of ₹8.28bn and net income of ₹2.09bn. At that date it held total assets of ₹13.57bn and shareholders' equity of ₹11.98bn.
Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2021-12-28. The firm is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals. The firm exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The firm's product portfolio consists of approximately 38 niche API products that address remedies in therapeutic segments, such as antihistamine, analgesic, vitamin, anesthetics and anti-asthmatics, among others. The firm has manufacturing facilities located in Maharashtra. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Dec 2021
- Employees
- 392
- Website
- supriyalifescience.com ↗
Leadership
Pay as last reported
- Dr. Satish WaghExecutive Chairman of the Board, since 2019₹116.1m
- Mr. Krishna RaghunathanChief Financial Officer
- Ms. Prachi SatheCompany Secretary and Compliance Officer
- Ms. Saloni WaghManaging Director, Whole-Time Director, since 2019₹24.8m
- Ms. Shivani WaghJoint Managing Director, Whole-Time Director, since 2019₹24.8m
- Mr. Balasaheb SawantWhole-Time Director, since 2017₹7.3m
- Ms. Smita WaghWhole-Time Director, since 2019₹16.9m
- Mrs. Neelam AroraNon-Executive Independent Director₹200,000
- Dr. Sunil BhagwatNon-Executive Independent Director₹40,000
- Shri. Dileep JainNon-Executive Independent Director₹250,000
- Mr. Dinesh ModiNon-Executive Independent Director₹320,000
- Dr. Ganapati YadavNon-Executive Independent Director₹40,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 61
- Environment
- 69
- Social
- 86
- Governance
- 27
- Direct emissions (scope 1)
- 451.01 t
- Energy emissions (scope 2)
- 10,995.31 t
- Women in the workforce
- 9.52%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Supriya Lifescience Ltd. manufactures 38 niche API products for antihistamine and analgesic therapies in Maharashtra.
- The company exports pharmaceutical chemicals to 86 countries across antihistamine, anesthetics, and anti-asthma segments.
- Supriya Lifescience's product portfolio includes Chlorphenamine Maleate and Cetirizine DiHCL for therapeutic use.
Weaknesses
- Supriya Lifescience Ltd. has only 392 employees, which may limit scalability in manufacturing.
- The firm's manufacturing facilities are limited to Maharashtra, restricting geographic expansion.
- Supriya Lifescience's focus on niche API products may reduce market diversification opportunities.
Opportunities
- Expanding exports to more countries in the antihistamine therapy segment could increase market share.
- Developing new API products in the analgesic and vitamin therapeutic areas offers growth potential.
- The firm can leverage its 38 niche API products to enter emerging markets in Asia.
Threats
- Competition from other pharmaceutical manufacturers in the antihistamine therapy segment poses a risk.
- Regulatory changes in 86 export countries could disrupt supply chains for pharmaceutical chemicals.
- Overreliance on niche API products may expose the company to market volatility.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.